Lumbar spinal stenosis (LSS) with neurogenic intermittent claudication (NIC) is one of the most common degenerative spinal changes in the elderly [1] [2] [3] . NIC is a specific symptom in patients with LSS and is characterized by increasing leg, buttock or groin pain with or without lower back pain when walking a cer tain distance or reclining. Forward bending or sitting leads to rapid relief of the symptoms.
LSS is seen frequently in clinical practice. Of all patients consulting a general practitioner for lower back pain, 3-4% have degenerative changes, which leads to NIC. Nearly 15% of patients seeing a specialist for lower back pain have radio graphically confirmed LSS [4] . Annual incidence rates of 5 per 100,000 have been reported [5] . In the USA, the annual cost of NIC to society from medical treatment and loss of productive work hours reaches tens of billions of dollars [6] . In Europe
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Nonoperative management is initially attempted with oral analgesics and physical therapy and the reg imen can be intensified by adding epidural injections, whilst in a third of all patients, this therapy decreases symptoms sufficiently. In the remaining twothirds of all cases, surgical treatment is necessary [7] . For patients over 65 years of age undergoing surgery, open decompression is most frequently performed [1, 8, 9] . One associated problem is surgical trauma to the osteoligamentous structures, which varies in severity depending on the extent of the operation performed.
A less invasive alternative is the implantation of an interspinous process decompression device (IPD). The gold standard of surgical treatment (open spinal decompression) of degenerative lumbar spinal ste nosis (DLSS) is more invasive than the investigated IPDs. Surgery time in the operating room is higher in comparison with the IPDs. Biomechanical studies have shown that IPDs significantly reduce intradiscal pressure as well as the facet load, and prevent nar rowing of the spinal canal and neural foramina [10, 11] . Previous studies have shown benefits for the use of implanted IPDs (e.g., XStop™) versus conservative therapy, especially with regards to quality of life [6, 12] .
For some patients with LSS, IPDs may be a viable alternative to the gold standard [13] . IPDs may be used either as 'stand alone' spacers or to augment open decompression by preventing instability [14] . The main idea behind their design is the limitation of dynamic extension in the affected segment [15] . Radiologic studies have demonstrated that the use of interspi nous devices affects spinal alignment as well as the dimensions of the spinal canal and neural foramina [16] [17] [18] .
The implantation of the IPDs can be done percuta neously through a 1.5 cm skin incision. This surgical approach is used for the Aperius™ PercLID device designed by Medtronic, Inc. A number of recently published studies have shown significantly better clinical outcome after implantation of the Aperius PercLID implant [19] [20] [21] [22] [23] .
The aim of this study is to evaluate safety and effi cacy of IPDs compared with conservative treatment of LSS. It is supported by the Faculty of Medicine, University of Cologne (Cologne, Germany), trial reg istration NCT01057641 [101] .
Material & methods
The study is designed as a randomized, thera pycontrolled trial in an ambulatory care setting at a university hospital. Patients presenting to the out patient clinic with degenerative LSS will be assessed against study inclusion and exclusion criteria. After patient informed consent and randomization, implantation of an IPD or conservative management will be implemented. Followup examinations will take place immediately after treatment during the hospital stay, and after 6 and 24 weeks, for a study duration of 6 months. Data will also be assessed after 12, 24, and 36 months for a supplemental study.
Experimental research in this trial will be carried out with the approval of the Ethics Committee of the Medical Faculty of the University of Cologne under the reference number 10-012. Research carried out in the trial will be in compliance with the Helsinki Declaration [24] .
Participants & recruitment
Patients over 50 years of age presenting to our out patient clinic with symptoms of degenerative lum bar spinal stenosis are eligible for trial inclusion. IPD implantation is not indicated until after 3 months of conservative therapy. The main inclusion criteria is the radiographically and clinic ally confirmed symp tomatic discoligamentous DLSS. Forward flexion leads to a rapid pain relief. The IPDs are not suitable for osseous DLSS and spondylolistesis greater then Meyerding 1. Patients with an absolute DLSS with a threshold diameter <10 mm will not be included. All inclusion criteria are summarized in Box 1.
Patients participating in parallel interventional studies as well as patients with lumbar scoliosis (>25° Cobb angle), spondylolisthesis > Meyerding 1, and/ or systematic disease are excluded from this study. Further exclusion criteria are summarized in Box 2.
Prerequisite to inclusion is degenerative LSS according to symptoms and MRI. Determining the symptomatic level of LSS is one of the unsolved prob lems. If one or more highgrade stenotic level is evi dent, all levels will be treated.
One of the main problems in orthopedic clinical trials is that it is difficult to comparatively random ize conservative treatment and surgical treatment. In our opinion we developed a study that respects this issue by the inclusion criteria. We will receive a homogeneous patient population that shows symp tomatic and radiographically confirmed DLSS with NIC, which can be be comparatively randomized.
Study subjects will be approached and recruited by experienced spine surgeons. An estimated 100 patients per year will be screened and a recruitment rate of 22 patients per year is anticipated (Figure 1 ).
Intervention
Patients will receive one of two treatments:
■ Percutaneous implantation of an interspinous device ('spacer');
■ Nonoperative treatment.
■ Control group: nonoperative treatment
The control group undergoes conservative manage ment with oral nonsteroidal antiinflammatories, other analgesics, physical therapy, and epidural pain treatment (3 × epidural injection). This is the gold standard for nonoperative therapy, and the current standard therapy in our hospital for this disease, when the patient is expressing moderate symptoms. The physical therapy is specifically tailored to NIC and consists of an isometric exercise program that is same for each patient. All patients will receive the same treatment, which consists of nonsteroidal antiinflammatories (600 mg ibuprofen 3 per day) and physical therapy. This regimen will be carried out as an inpatient for 7 days. The physical therapy program will continue for 6 weeks (For schedule, see Tables 1 & 2) .
■ Intervention group: interspinous device
Patients of the experimental intervention group will receive the percutaneously implanted interspinous device. Insertion of the standalone spacer will be conducted under spinal or general anesthesia, with the patient placed in the prone position. The trocar will be introduced and pushed forward under posi tion monitoring (Xray) to the interspinous space. For optimal decompression, the trocar diameter can be increased. Once optimal diameter is identified, the spacer can be positioned between the spinous processes of the affected level and the wings of the spacer can then be unfolded. Patients will only be discharged after sufficient convalescence with an unremarkable wound. A hospital stay of 2-3 days will be necessary.
Outcome measures & assessments ■ Primary outcome measures: SF-36 physical component summary
Our investigation focuses on the subjective and objective benefits for the patient. Functional out comes will be evaluated using the SF36 score at 6 weeks and 6 months after treatment (evaluations at 12, 24, and 36month follow ups will be performed in a supplemental study ■ Severe heart insufficiency (New York Heart Association classification III-IV) ■ Blood coagulation disorder or blood thinning therapy ■ Cortisone intake more than one month in the 12 months before randomization ■ Simultaneous participation in another clinical trial in the 30 days before randomization ■ Known allergy or intolerance to the implants ■ Dependency on investigator ■ Lack of familiarity with the German language ■ Placement in an institution by governmental or juridical advice ■ Absent legal capacity ■ Pregnancy affect the SF36 dimensions of physical function ing, rolephysical, and bodily pain, which contrib ute most to factor loadings of the PCS. Therefore we decided to use the SF36 instead of the Oswestry Disability Index. The primary end point is the change from baseline to 6 weeks and 6 months. After this time, substantial dropout or conversion fraction is not expected, so that valid assessment should be pos sible. Of course, the follow up at 36 months will give essential information regarding longterm outcomes and the effects of conversion, in particular the num ber of patients in both groups eventually requiring open surgery.
■ Secondary outcome measures
This trial focuses on the subjective and objective ben efits for the patient, therefore the following secondary end points will be analyzed:
■ Patient satisfaction regarding treatment by both experimental and control groups as measured on the ZCQ comparing baseline values with those at Lost to follow up or discontinued intervention n = 1 (expected)
Primary and secondary measures 6 weeks and 6 months after treatment (n = 10) Primary and secondary measures 6 weeks and 6 months after treatment (n = 10) Lost to follow up or discontinued intervention n = 1 (expected) Conservative treatment n = 11 hospital discharge, at 6 weeks, and 6 months (for the supplemental study also 12, 24, and 36 months) after initiation of therapy;
■ Average change in physical activity as measured on the ZCQ comparing baseline values with those at hospital discharge, at 6 weeks, and 6 months (for the supplemental study also 12, 24, and 36 months) after initiation of therapy;
■ Average change of the symptom severity as measured on the ZCQ comparing baseline values with those at hospital discharge at 6 weeks and 6 months (for the supplemental study also 12, 24, and 36 months) after initiation of therapy;
■ Walking distance according to treadmill measures comparing baseline values with those at hospital dis charge, at 6 weeks, and 6 months (for the supplemen tal study also 12, 24, and 36 months) after initiation of therapy;
■ Global patient health status as measured with the SF36 comparing baseline values to those at hospital discharge at 6 weeks and 6 months (for the supple mental study also 12, 24, and 36 months) after initiation of therapy;
■ Secondary end point: at each visit, patients will be asked to rate their subjective pain using a Visual Analog Scale; ■ Treatment complications: general (e.g., deep venous thrombosis, pneumonia and urinary tract infection) and treatmentspecific (e.g., implant failure, spinous process fracture, epidural hematoma and infection);
■ Longterm effects of surgery (implantloosening, accelerated degeneration of the adjacent segments) will be analyzed in the follow ups.
Sample size
Our target recruitment is 22 patients. We assume a loss at follow up of 10%, leaving 20 patients available for the final analysis. The normalized form of the SF36™ PCS (mean: 50; SD: 10) is assumed. With this number of patients, using a twosided ttest, a normalized PCS score difference of 11 will be achieved. Two or more could be detected with a power of 80% and a = 0.05. This trial is developed as a pilot trial to detect the dif ference between the two groups. After data analysis another study with a larger sample size will be designed to improve the statistic significance.
Randomization
The randomization of patients into intervention and control groups is performed using blocks of randomly varied length in order to maintain balance of alloca tion while preventing predictability. Randomization is stratified by single or multisegmental disease. A con tainer with the sequentially numbered, sealed envelopes is stored in a locked cupboard that only the investi gator can open. The random allocation sequence and the sealed envelopes will be generated by the Institute of Medical Statistics, Informatics, and Epidemiology of the university conducting the trial. Enrollment and randomization will be executed by the investigator.
Results
The primary ana lysis will be according to intention to treat. Repeated SF36 subscores over time (primary: baseline, 6 weeks, 6, 12, 24, and 36 months) will be analyzed by mixedeffects models (using specific con trasts) with the variables: treatment, time and multi ple segment DLSS according to intention to treat. The hypotheses on changes in bodily pain and physical function will be addressed in a fixed sequence (thus, no correction for multiplicity is required). Missing at random will be assumed and the impact of plausible missing mechanisms (i.e., missing not at random) will be explored within the study results. The ana lysis will be repeated according to treatment actually received (as treated). Subgroup analyses will be conducted accord ing to gender and multiple segment DLSS (if this is possible with 22 randomized patients). Analysis of sec ondary end points will follow the same procedure (i.e., longitudinal regression). Safety analysis (complications/ adverse events) will be descriptive, for instance, using tables and listings.
Discussion
It is possible that IPDs improve the outcome of LSS. To date, however, there are few convincing published data regarding these percutaneously inserted implants. In an observational study, Galarza reported improvement in 40 patients after minimally invasive IPD implanta tion [21] . Patients were assessed by ZCQ and a Visual Analog Scale. Between 2007 and 2008, Nardi implanted IPDs in 152 patients and reported the postoperative results [22] . No serious adverse events were recorded. In one case the IPD was not implanted because of hyper trophic facet joints, and in two cases therapeutic fail ure was observed. Visual Analog Scale and ZCQ scores improved significantly [22] . Van Meirhaeghe et al. could show that the safety and effectiveness of the Aperius device offer a minimally invasive option for the treat ment of DLSS [25] . According to clinicaltrials.gov, two studies are ongoing and recruiting and each is comparing two different IPDs in a randomized trial [102, 103] . In addi tion to an observational clinical followup study of the Aperius IPD that has finished recruiting [104] , a feasibility study of NLProw™ Interspinous Spacer is ongoing, but not recruiting [105] . Finally, one obser vational longterm follow up of the XSTOP ® IPD has been completed [106] .
The aforementioned studies are encouraging for the use of IPDs. On the other hand Verhoof et al. reported on a high failure rate after short follow up in patients with spinal stenosis caused by degenerative spondy lolisthesis, but did not recommend the IPDs for the treatment of spinal stenosis caused by degenerative spondylolisthesis [26] .
However, to determine a superior effect of IPDs ver sus other treatment options for LSS/NIC, randomized clinical trials are indispensable. To our knowledge, no published or ongoing studies fulfill these conditions. Thus, we offer a randomized clinical trial comparing the Aperius IPD with conservative treatment.
On the other hand, our pilot study design has to be considered. The measurement of statistically signifi cant effects and a large effect magnitude require large sample sizes. While obtaining our data, we recommend discussion of potential efficacy and if possible, further multicenter, randomized controlled trials (RCTs) to offer general recommendations for spine surgeons. The conservative treatment in this trial represents an inten sified nonoperative treatment that we perform in our hospital. In this trial we want to see if the IPDs have the same clinical value such as the intensified conservative treatment.
Future Perspective
There are specific difficulties to be faced when exe cuting clinical trials related to surgical procedures (e.g., the learning curve of the surgeon, blinding). From our experience, recruitment in orthopedic tri als including random ization is always challenging, especially comparing operative and nonoperative treatment. As a result, surgical RCT are underrep resented in the total number of RCTs and in the sci entific literature. Evidencebased surgical therapy is essential for further development of a high quality surgical standard in spine surgery, which will also provide quality assurance in the future. First we want to analyze the new surgical treatment in comparison to the conservative treatment. The next step would be a RCT of IPDs versus open spinal decompression. Longterm effects of surgery (implantloosening, accelerated degeneration of the adjacent segments) will be analyzed in the follow ups.
Executive summary
■ Lumbar spinal stenosis (LSS) with neurogenic intermittent claudication is one of the most common degenerative spinal diseases in the elderly.
■ Another relatively new operative alternative is the use of interspinous process decompression (IPD).
■ To date, there is no convincing evidence that these devices provide any patient benefits.
■ Biomechanical studies have shown that IPDs significantly reduce intradiscal pressure, as well as the facet load, and prevent narrowing of the spinal canal and neural foramina.
■ For some patients with LSS, IPDs may be a viable alternative to the gold standard.
■ This study is intended as a prospective, randomized, pilot study to compare the safety and effectiveness of a minimally-invasive, percutaneously implanted IPDs with nonoperative treatment of LSS.
■ Outcome measurements will include objective parameters such as pain-free walking distance and frequency of pain medication use. The Zurich Claudication Questionnaire, a Visual Analog Scale, SF-36 scores, patients' overall status, and clinical examinations will be assessed.
■ One of the main problems in orthopedic clinical trials is that it is difficult to comparatively randomize conservative treatment and surgical treatment. In our opinion we developed a study that respects this issue by our inclusion criteria. We will receive a homogeneous patient population that shows symptomatic and radiographically confirmed degenerative LSS with neurogenic intermittent claudication, which can be comparatively randomized.
■ As new surgical techniques are developed for the treatment of LSS, it is important to evaluate the effectiveness of competing strategies. With this study, not only patient-based scores, but also objective assessments will be used to quantify patient-derived benefits of therapy. 
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